Intravenous immunoglobulin therapy in rheumatic diseases

Nature Reviews Rheumatology

Volumn 7, Issue 6, 2011, Pages 349-359

  Bayry, Jagadeesh ^a   Negi, Vir Singh ^b   Kaveri, Srini V ^a  

^a INSERM   (France)

^b JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FC RECEPTOR; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISOLONE; RECOMBINANT PROTEIN; RECOMBINANT SIALYLATED IMMUNOGLOBULIN G FC; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ANAPHYLAXIS; ANCA ASSOCIATED VASCULITIS; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ASEPTIC MENINGITIS; ASTHMA; AUTOIMMUNE HEMOLYTIC ANEMIA; BURNING SENSATION; CATABOLISM; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CD4+ CD25+ FOXP3+ T CELL; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DISEASE; DERMATOMYOSITIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTAMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; GLOMERULONEPHRITIS; HUMAN; HYPOTENSION; IDIOPATHIC INFLAMMATORY MYOPATHY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREGULATION; INFARCTION; INFLAMMATORY INFILTRATE; INTRAVASCULAR HEMOLYSIS; JUVENILE DERMATOMYOSITIS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; MUSCLE STRENGTH; MYOPATHY; MYOSITIS; OFF LABEL DRUG USE; PAIN; PEMPHIGUS VULGARIS; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PRURITUS; QUALITY CONTROL; RECOMMENDED DRUG DOSE; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SJOEGREN SYNDROME; STIFF MAN SYNDROME; STROKE; SWELLING; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VOMITING;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; RHEUMATIC DISEASES;

EID: 79958140473     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.61     Document Type: Review

References (120)

1. Kazatchkine, M. D. & Kaveri, S. V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345, 747-755 (2001).
2. Galeotti, C., Bayry, J., Kone-Paut, I. & Kaveri, S. V. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun. Rev. 9, 441- 448 (2010).
3. Kato, H. et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 94, 1379-1385 (1996). (Pubitemid 26307269)
4. Burns, J. C. et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J. Infect. Dis. 192, 344-349 (2005). (Pubitemid 40993406)
5. Newburger, J. W. et al. A single intravenous infusion of ã-globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 324, 1633-1639 (1991).
6. Oates-Whitehead, R. M. et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews, Issue 4. Art. No.:CD004000. doi:10.1002/14651858. CD004000 (2003).
7. Gupta, M. et al. Cytokine modulation with immune ã-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment. J. Clin. Immunol. 21, 193-199 (2001). (Pubitemid 32434306)
8. + T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 111, E140-E147 (2003).
9. Abe, J. et al. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 174, 5837-5845 (2005). (Pubitemid 40593229)
10. + regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
11. + regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. Am. J. Pathol. 174, 1575-1587 (2009).
12. Esensten, J. H., Wofsy, D. & Bluestone, J. A. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 560-565 (2009).
13. Bayry, J. Autoimmunity: CTLA-4: a key protein in autoimmunity. Nat. Rev. Rheumatol. 5, 244-245 (2009).
14. Annunziato, F., Cosmi, L., Liotta, F., Maggi, E. & Romagnani, S. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat. Rev. Rheumatol. 5, 325-331 (2009).
15. Olivito, B. et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin. Exp. Rheumatol. 28 (Suppl. 57), 93-97 (2010).
16. Jia, S., Li, C., Wang, G., Yang, J. & Zu, Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin. Exp. Immunol. 162, 131-137 (2010).
17. + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111, 715-722 (2008).
18. Kessel, A. et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 179, 5571-5575 (2007).
19. H17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 127, 823-830 (2011).
20. Orange, J. S. et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 117 (Suppl.), S525-S553 (2006).
21. Tremoulet, A. H. et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J. Pediatr. 153, 117-121 (2008).
22. Abe, J. et al. Elevated granulocyte colony- stimulating factor levels predict treatment failure in patients with Kawasaki disease. J. Allergy Clin. Immunol. 122, 1008-1013 (2008).
23. Fury, W. et al. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum. Immunol. 71, 865-873 (2010).
24. Burns, J. C. et al. Infliximab treatment for refractory Kawasaki syndrome. J. Pediatr. 146, 662-667 (2005). (Pubitemid 40616253)
25. Rider, L. G. & Miller, F. W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. 23, 619-655 (1997). (Pubitemid 27397123)
26. Massa, M. et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum. 46, 3015-3025 (2002). (Pubitemid 35315896)
27. Sansome, A. & Dubowitz, V. Intravenous immunoglobulin in juvenile dermatomyositis- four year review of nine cases. Arch. Dis. Child. 72, 25-28 (1995).
28. Al-Mayouf, S. M., Laxer, R. M., Schneider, R., Silverman, E. D. & Feldman, B. M. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol. 27, 2498-2503 (2000).
29. Donofrio, P. D. et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40, 890-900 (2009).
30. Prieur, A. M. et al. High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin. Exp. Rheumatol. 8, 603-608 (1990).
31. Silverman, E. D. et al. Intravenous ã globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 33, 1015-1022 (1990). (Pubitemid 20226356)
32. Silverman, E. D. et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J. Rheumatol. 21, 2353-2358 (1994).
33. Taylor, P. C. & Feldmann, M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 578-582 (2009).
34. Santmyire-Rosenberger, B. & Dugan, E. M. Skin involvement in dermatomyositis. Curr. Opin. Rheumatol. 15, 714-722 (2003). (Pubitemid 38156297)
35. Dalakas, M. C. Immunotherapy of myositis: issues, concerns and future prospects. Nat. Rev. Rheumatol. 6, 129-137 (2010).
36. H1 cytokine-producing cells. Arthritis Rheum. 50, 199-208 (2004). (Pubitemid 38084305)
37. Grundtman, C., Malmstrom, V. & Lundberg, I. E. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res. Ther. 9, 208 (2007).
38. Dalakas, M. C. et al. A controlled trial of high- dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993-2000 (1993). (Pubitemid 24015043)
39. Amemiya, K., Semino-Mora, C., Granger, R. P. & Dalakas, M. C. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin. Immunol. 94, 99-104 (2000). (Pubitemid 30067874)
40. Raju, R. & Dalakas, M. C. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128, 1887-1896 (2005). (Pubitemid 41373661)
41. Basta, M. & Dalakas, M. C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729-1735 (1994). (Pubitemid 24348207)
42. Barbasso Helmers, S. et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann. Rheum. Dis. 66, 1276-1283 (2007).
43. H17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 46, 297-301 (2009).
44. Elovaara, I. et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 15, 893-908 (2008).
45. Marie, I. et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. (Hoboken) 62, 1748-1755 (2010).
46. Joseph, A. et al. Immunologic rheumatic disorders. J. Allergy Clin. Immunol. 125 (Suppl. 2), S204-S215 (2010).
47. Cherin, P. et al. Efficacy of intravenous ã-globulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am. J. Med. 91, 162-168 (1991).
48. Cherin, P. et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty- five adult patients. Arthritis Rheum. 46, 467-474 (2002). (Pubitemid 34136585)
49. Dalakas, M. C. et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo- controlled study. Neurology 48, 712-716 (1997). (Pubitemid 27120112)
50. Walter, M. C. et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247, 22-28 (2000). (Pubitemid 30162508)
51. Chen, M. & Kallenberg, C. G. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat. Rev. Rheumatol. 6, 653-664 (2010).
52. Richter, C. et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin. Exp. Immunol. 101, 2-7 (1995).
53. Jayne, D. R. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93, 433-439 (2000). (Pubitemid 30459921)
54. Martinez, V. et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 58, 308-317 (2008).
55. Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929-939 (2008). (Pubitemid 351397092)
56. Charles, N., Hardwick, D., Daugas, E., Illei, G. G. & Rivera, J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat. Med. 16, 701-707 (2010).
57. Crispín, J. C. et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 16, 47-57 (2010).
58. Kaveri, S. V., Mouthon, L. & Bayry, J. Basophils and nephritis in lupus. N. Engl. J. Med. 363, 1080-1082 (2010).
59. Crispín, J. C., Kyttaris, V. C., Terhorst, C. & Tsokos, G. C. T cells as therapeutic targets in SLE. Nat. Rev. Rheumatol. 6, 317-325 (2010).
60. Toubi, E., Kessel, A. & Shoenfeld, Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum. Immunol. 66, 395-402 (2005). (Pubitemid 40615795)
61. Micheloud, D., Calderón, M., Caparrros, M. & D'Cruz, D. P. Intravenous immunoglobulin therapy in severe lupus myocarditis: good outcome in three patients. Ann. Rheum. Dis. 66, 986-987 (2007). (Pubitemid 46999810)
62. Boletis, J. N., Ioannidis, J. P., Boki, K. A. & Moutsopoulos, H. M. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354, 569-570 (1999). (Pubitemid 29381378)
63. Shoenfeld, Y. et al. Efficacy of IVIg affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. 14, 1303-1311 (2002). (Pubitemid 35331427)
64. Nikolova, K. A., Tchorbanov, A. I., Djoumerska- Alexieva, I. K., Nikolova, M. & Vassilev, T. L. Intravenous immunoglobulin up-regulates the expression of the inhibitory FcãIIB receptor on B cells. Immunol. Cell Biol. 87, 529-533 (2009).
65. Tha-In, T., Bayry, J., Metselaar, H. J., Kaveri, S. V. & Kwekkeboom, J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 29, 608-615 (2008).
66. Seite, J. F., Shoenfeld, Y., Youinou, P. & Hillion, S. What is the contents of the magic draft IVIg? Autoimmun. Rev. 7, 435-439 (2008).
67. Bayry, J. et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-α present in serum from patients with systemic lupus erythematosus. Arthritis Rheum. 48, 3497-3502 (2003). (Pubitemid 37531915)
68. Espinosa, G. & Cervera, R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat. Rev. Rheumatol. 6, 296-300 (2010).
69. Carreras, L. D., Perez, G. N., Vega, H. R. & Casavilla, F. Lupus anticoagulant and recurrent fetal loss: successful treatment with ã-globulin. Lancet 2, 393-394 (1988).
70. Branch, D. W. et al. A multicenter, placebo- controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am. J. Obstet. Gynecol. 182, 122-127 (2000). (Pubitemid 30074379)
71. Hsiao, G. R., Wolf, R. E. & Kimpel, D. L. Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J. Clin. Rheumatol. 7, 336-339 (2001). (Pubitemid 32977733)
72. Blank, M. et al. The efficacy of specific IVIg anti- idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. 19, 857-865 (2007). (Pubitemid 47241894)
73. Pierangeli, S. S., Espinola, R., Liu, X., Harris, E. N. & Salmon, J. E. Identification of an Fc ã receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype. Arthritis Rheum. 44, 876-883 (2001). (Pubitemid 32319780)
74. Sher, G. et al. The selective use of heparin/ aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody- positive women undergoing in vitro fertilization. Am. J. Reprod. Immunol. 40, 74-82 (1998). (Pubitemid 28380061)
75. Vora, S. K., Asherson, R. A. & Erkan, D. Catastrophic antiphospholipid syndrome. J. Intensive Care Med. 21, 144-159 (2006).
76. Cervera, R. et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J. Autoimmun. 32, 240-245 (2009).
77. Trojanowska, M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat. Rev. Rheumatol. 6, 453-460 (2010).
78. Nacci, F. et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann. Rheum. Dis. 66, 977-979 (2007). (Pubitemid 46999806)
79. Levy, Y. et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open- label study. Arthritis Rheum. 50, 1005-1007 (2004). (Pubitemid 38326203)
80. Szekanecz, Z. et al. Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: follow-up of immunopathological and clinical effects. Clin. Rheumatol. 28, 347-350 (2009).
81. Amital, H. et al. Fibrosis regression induced by intravenous ã-globulin treatment. Ann. Rheum. Dis. 62, 175-177 (2003). (Pubitemid 36135396)
82. Dalakas, M. C. et al. High-dose intravenous immune globulin for stiff-person syndrome. N. Engl. J. Med. 345, 1870-1876 (2001). (Pubitemid 33716561)
83. Takahashi, Y., Takata, T., Hoshino, M., Sakurai, M. & Kanazawa, I. Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjögren's syndrome. IV immunoglobulin. Neurology 60, 503-505 (2003). (Pubitemid 36188253)
84. Kaaja, R. & Julkunen, H. Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum. 48, 280-281 (2003).
85. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313, 670-673 (2006). (Pubitemid 44201145)
86. Anthony, R. M., Wermeling, F., Karlsson, M. C. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIg. Proc. Natl Acad. Sci. USA 105, 19571-19578 (2008).
87. Kaveri, S. V., Lacroix-Desmazes, S. & Bayry, J. The antiinflammatory IgG. N. Engl. J. Med. 359, 307-309 (2008).
88. Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533 (2008). (Pubitemid 351600384)
89. Ballow, M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127, 315-323 (2011).
90. Radosevich, M. & Burnouf, T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 98, 12-28 (2010).
91. Katz, U., Achiron, A., Sherer, Y. & Shoenfeld, Y. Safety of intravenous immunoglobulin (IVIg) therapy. Autoimmun. Rev. 6, 257-259 (2007). (Pubitemid 46274552)
92. Berger, M. in Clinical Focus on Primary Immune Deficiencies (ed. Sullivan, K.) Subcutaneous IgG therapy in immune deficiency diseases. Issue 13, 1-12 (Immune Deficiency Foundation, Townson, 2008).
93. Gürcan, H. M., Keskin, D. B. & Ahmed, A. R. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun. Rev. 9, 553-559 (2010).
94. Danieli, M. G., Pettinari, L., Moretti, R., Logullo, F. & Gabrielli, A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun. Rev. 10, 144-149 (2011).
95. Lobo, E. D., Hansen, R. J. & Balthasar, J. P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645-2668 (2004). (Pubitemid 39506617)
96. Junghans, R. P. & Anderson, C. L. The protection receptor for IgG catabolism is the â2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl Acad. Sci. USA 93, 5512-5516 (1996).
97. Morell, A. in Intravenous Immunoglobulins in Clinical Practice (eds. Lee, M. E. & Strand, V. ) Ch. 1, Pharmacokinetics of intravenous immunoglobulin preparations. 1-18 (Marcel Dekker Inc., New York, 1997).
98. Bonilla, F. A. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allerg y Clin. Nor th Am. 28, 803-819 (2008).
99. Gustafson, R. et al. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin. Exp. Immunol. 152, 274-279 (2008). (Pubitemid 351520905)
100. Imbach, P. et al. High-dose intravenous ã-globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1, 1228-1231 (1981).
101. Blanchette, V. et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 344, 703-707 (1994). (Pubitemid 24281420)
102. Hughes, R. A. et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136-144 (2008).
103. Bayry, J., Kazatchkine, M. D. & Kaveri, S. V. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat. Clin. Pract. Neurol. 3, 120-121 (2007). (Pubitemid 46403934)
104. Ahmed, A. R., Spigelman, Z., Cavacini, L. A. & Posner, M. R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355, 1772-1779 (2006). (Pubitemid 44631360)
105. Vo, A. A. et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359, 242-251 (2008). (Pubitemid 352008439)
106. Bayry, J., Lacroix-Desmazes, S., Kazatchkine, M. D. & Kaveri, S. V. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat. Clin. Pract. Rheumatol. 3, 262-272 (2007). (Pubitemid 46711473)
107. Micheloud, D. et al. Efficacy and safety of etanercept, high-dose intravenous ã-globulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 15, 881-885 (2006). (Pubitemid 46044921)
108. Chang, D. K. et al. Induction of remission with intravenous immunoglobulin and cyclophosphamide in steroid-resistant Evans' syndrome associated with dermatomyositis. Clin. Rheumatol. 20, 63-66 (2001).
109. Saadeh, C., Bridges, W. & Burwick, F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South. Med. J. 88, 866-870 (1995).
110. Danieli, M. G. et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun. Rev. 9, 124-127 (2009).
111. Sharma, K. G. et al. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transpl. Immunol. 23, 117-120 (2010).
112. Anthony, R. M. et al. Recapitulation of IVIg anti- inflammatory activity with a recombinant IgG Fc. Science 320, 373-376 (2008). (Pubitemid 351555659)
113. Hurez, V. et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 90, 4004-4013 (1997). (Pubitemid 27484054)
114. Kanamaru, Y. et al. Inhibitory ITAM signaling by Fc á RI-FcR ã chain controls multiple activating responses and prevents renal inflammation. J. Immunol. 180, 2669-2678 (2008).
115. Brennan, V. M., Salomé-Bentley, N. J. & Chapel, H. M. Prospective audit of adverse reactions occurring in 459 primary antibody- deficient patients receiving intravenous immunoglobulin. Clin. Exp. Immunol. 133, 247-251 (2003). (Pubitemid 36918599)
116. Caress, J. B., Cartwright, M. S., Donofrio, P. D. & Peacock, J. E. Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology 60, 1822-1824 (2003). (Pubitemid 36737082)
117. Hamrock, D. J. Adverse events associated with intravenous immunoglobulin therapy. Int. Immunopharmacol. 6, 535-542 (2006).
118. Achermann, F. J., Julmy, F., Gilliver, L. G., Carrel, T. P. & Nydegger, U. E. Soluble type A substance in fresh-frozen plasma as a function of ABO and Secretor genotypes and Lewis phenotype. Transfus. Apher. Sci. 32, 255-262 (2005). (Pubitemid 40804616)
119. Jarius, S. et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFá-dependent and Fc-receptor-independent way. Blood 109, 4376-4382 (2007). (Pubitemid 46743406)
120. Desai, S. H., Chouksey, A., Poll, J. & Berger, M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J. Allergy Clin. Immunol. 124, 854-856 (2009).